In conclusion, CD19 CAR-T cell therapy for R/R t(8;21) AML with CD19 aberrant expression is effective and safe, which broadens the application of CD19 CAR-T cell therapy in hematological malignancies, beyond B-cell malignancies. Here, CD19 is linked to acute myeloid leukemia.